Fig. 1From: Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinomaThe workflow for identification of candidate biomarkers for early diagnosis of lung adenocarcinoma (LUAD). The workflow contains two parts: bioinformatics analysis and clinical validation. The bioinformatics analysis contains upregulated differentially expressed genes (DEGs) screening and genes encoding secreted proteins predicted by the majority decision-based method. The expressions of the identified secreted proteins are validated using the TCGA and CPTAC databases. The clinical validation was carried out using the plasma samples of 26 early-stage LUAD patients and 11 healthy donorsBack to article page